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Summary
The objective of this study was to target drug delivery to radiation-induced neoantigens, which include activated receptors
within the tumor vasculature. These responses include posttranslational changes in pre-existing proteins, which can be
discovered by phage-displayed peptide libraries administered to mice bearing irradiated tumors. Phage-displayed peptides
recovered from irradiated tumors included the amino acid sequence RGDGSSV. This peptide binds to integrins within the
tumor microvasculature. Immunohistochemical staining of irradiated tumors showed accumulation of fibrinogen receptor
2b3 integrin. We studied tumor targeting efficiency of ligands to radiation-induced 2b3. Radiopharmaceuticals were
localized to irradiated tumors by use of 2b3 ligands conjugated to nanoparticles and liposomes. Fibrinogen-conjugated
nanoparticles bind to the radiation-activated receptor, obliterate tumor blood flow, and significantly increase regression
and growth delay in irradiated tumors. Radiation-guided drug delivery to tumor blood vessels is a novel paradigm for
targeted drug delivery.
Introduction 1999; Ellerby et al., 1999; Fox and Harris, 1997; Molema et
al., 1997; Pasqualini and Ruoslahti, 1996; Hood et al., 2002).
Tumor-specific drug delivery has the potential to minimize toxic- Inducible antigens include proteins in the microvasculature of
ity to normal tissues and improve bioavailability of cytotoxic irradiated tumors, which are antigenic targets for site-specific
agents to neoplasms (Arap et al., 1998; Hallahan et al., 1995a; drug delivery to tumor blood vessels (Hallahan et al., 1995b,
Kasahara et al., 1994). Existing site-specific drug delivery sys- 1996, 1998). We studied the tumor-targeting efficiency of phage
tems include adenovirus-targeted delivery to endothelial recep- peptide libraries that bind to radiation-induced proteins.
tor v3 (Brooks et al., 1994; Wickham et al., 1995), and tumor- Studies of irradiated tumor microvasculature have identified
specific antigens (Ito et al., 1991; Kirpotin, 1997; Manome et receptors and adhesion molecules that contribute to the biologi-
al., 1994). Antibody conjugation to cytotoxic agents has shown cal response to therapy (Hallahan et al., 1998, 1999). Although
promise in achieving the goal of tumor-targeted cytotoxicity changes in protein expression can be measured, posttransla-
tional modification of integrins, receptors, and adhesion mole-(Hellstrom et al., 1996; Pastan, 1997). This approach may be
limited by the small subsets of tumors that can be targeted by cules might best be detected by use of phage display peptide
libraries (Arap et al., 1998; Forrer et al., 1999; Rajotte and Ruos-these antibodies and by poor biodistribution of antibodies into
solid tumors (Dvorak et al., 1991; Jain, 1997; Shockley et al., lahti, 1999). We utilized phage peptide libraries to (Zwick et al.,
1998) discover radiation-activated receptors. Peptide binding1991). Alternative approaches to target all neoplasms exploit
integrins and antigens on proliferating microvasculature (Arap has been well characterized for ligand interaction with integrins.
Among the most prevalent sequence motifs is the amino acidet al., 1998; Baillie et al., 1995; Brooks et al., 1994; Burg et al.,
S I G N I F I C A N C E
Targeted drug delivery is achieved by use of antibodies that bind selectively to tumor antigens. This strategy of targeted therapy
may be limited by the low percentage of neoplasms that express any given antigen. Alternatively, neoantigens are induced within
neoplasms following treatment with ionizing radiation. To increase the spectrum of antigenic targets for drug delivery, radiation-
induced neoantigens within tumor microvasculature were targeted for drug delivery. Here we show that ligand binding to radiation-
activated receptors achieves site-specific drug delivery to irradiated tumor microvasculature. The biologic effect of this targeting
strategy is obliteration of tumor blood flow by ligand-conjugated nanoparticles. Obliteration of tumor microcirculation significantly
enhances tumor regression and growth delay. This paradigm of site-specific drug delivery compliments existing forms of targeted
drug delivery.
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sequence arginine-glycine-aspartic acid, RGD, which is a major receptors that bind the RGD peptide include the 1, 3, and
recognition system for cell adhesion and binds to approximately 5 chains, which heterodimerize with the v chain to form the
half of the known integrins. Integrins are heterodimeric proteins v3 integrin on the endothelium or with the 2b chain on plate-
in which each of the subunits contributes to ligand specificity lets (Ruoslahti, 1996). To determine whether the level of these
and contains binding sites for the ligand. The 3 chain of integ- integrins increases in response to irradiation, immunohisto-
rins v3 and 2b3 becomes crosslinked to the RGD peptide chemical staining and Western immunoblots were used to study
on the ligand (Smith and Cheresh, 1988). During RGD crosslink- integrins in irradiated tumors. Microscopic photographs of tu-
ing of 2b3, RGD binds to the  subunit while the KQAGDV mor sections are shown in Figure 1. Immunohistochemical stain-
sequence motif binds primarily to the  subunit (Santoro and ing for integrin 2b3, and the v chain of integrin v3, revealed
Lawing, 1987). We utilized the native 2b3 ligand, fibrinogen, increased levels of the 3 chain (Figure 1B) and the 2b chain
to achieve targeted drug delivery of radiopharmaceuticals and (Figure 1D) within the lumen of the microvasculature of tumors
liposomes to irradiated tumor microvasculature. isolated 6 hr after irradiation, but no increase in untreated control
Tumor blood vessels have been shown to be a therapeutic tumors (Figures 1A and 1C). Conversely, staining for the v
target in the treatment of neoplastic diseases (Folkman, 1995). chain did not increase after irradiation (Figures 1E and 1F). To
Angiolytic therapy differs from angiostatic therapy in that exist- determine whether 2b and 3 chain staining correlated with
ing tumor blood flow is destroyed as opposed to the prevention platelet accumulation, tumor sections were stained for P-selec-
of neovascular development, which results from antiangiogen- tin. This showed P-selectin staining in the endothelium prior to
ics. In the present study, obliteration of tumor blood flow was irradiation, and P-selectin accumulation in the lumen of tumor
achieved by targeting drug delivery to radiation-activated recep- blood vessels after irradiation (Figures 1G and 1H). To verify
tor within tumor blood vessels. Destruction of blood flow was that 2b3 accumulates within irradiated tumor blood vessels,
achieved by use of nanospheres, which are particles that contain Western immunoblot using anti-2b antibody was performed.
pharmaceuticals and are designed to embolize tumor microvas- Protein extracted from tumors shown in Figures 1C and 1D was
culature (McGinity and O’Donnell, 1997). A common nanopar- separated by SDS-PAGE. Figure 1I shows increased 2b chain
ticle core is albumin, which can be loaded with drugs that will of the 2b3 integrin beginning at 3 hr and persisting at 6 hr afterbe released for prolonged periods of time. Vascular administra- tumor irradiation.
tion of nanoparticles has been designed to localize therapy to
tumor blood vessels (Llovet). For example, antibodies have been
Ligand binding to receptor in irradiated
linked to microspheres to achieve site specificity. We conju-
tumor vasculature
gated albumin nanoparticles to ligand that binds to radiation-
Possible sites of RGDGSSV peptide binding include receptorsactivated receptor. This approach achieved obliteration of tumor
in the vascular lumen or vascular wall. To determine the patternmicrovascular blood flow and significant enhancement of tumor
of RGDGSSV peptide binding within irradiated tumor blood ves-regression and tumor growth delay.
sels, we utilized the dorsal skin fold tumor vascular window
(Geng et al., 2001). LLC tumors were implanted into intravitalResults
windows on C57BL6 mice. FITC-labeled peptide was adminis-
tered by tail vein injection and tumors were irradiated with 6 Gy.Peptides recovered from irradiated tumors
Figure 2 shows fluorescent microscopic photographs obtainedThe primary objective of this study was to identify receptors
at 6 hr after irradiation. Irradiated tumors showed RGDGSSVand/or cell adhesion molecules in tumor vasculature that are
peptide binding within the lumen of microscopic blood vesselsactivated or induced by irradiation. These physiologic responses
(Figure 2C). Control scrambled peptide was used to determineof pre-existing proteins include conformational changes and
whether radiation-induced peptide binding was nonspecific.transport of sequestered proteins, which cannot be detected
Control peptide showed no increase in binding and blood ves-by use of differential screening of tumors. To identify candidate
sels in unirradiated tumors showed no increase in RGDGSSVpeptides that bind within irradiated tumor microvasculature, the
peptide binding.phage peptide library was injected by tail vein into mice bearing
Platelet activation could account for RGDGSSV peptideirradiated GL261 and LLC tumors. Phage were recovered from
binding in irradiated tumors. Fibrinogen has two RGD peptidestumors and sequentially re-administered to six mice bearing
on the  chain, which participate in binding to activated 2b3irradiated tumors. Fifty bacterial colonies were selected from
receptor on platelets. To determine whether fibrinogen bindseach of two distinct tumor types. Of the peptides recovered
within blood vessels of mice bearing both irradiated and controlfrom each of the two distinct irradiated tumors, 22% had peptide
tumors, we administered biotinylated fibrinogen by tail vein in-sequence RGDGSSV. We compared this recombinant phage
jection. Fluorescent microscopy of FITC-conjugated avidinto wild-type phage for binding within irradiated tumors. The
staining of biotinylated fibrinogen showed fibrinogen accumula-frequency of recovery of the RGDGSSV phage irradiated tumors
tion throughout the lumen of irradiated tumor (Figure 2E) aswas compared to that of untreated tumors in the same mice.
compared to the patchy staining in untreated control tumorOf the 106 RGDGSSV phage injected, 31  9 were recovered
(Figure 2D). To determine whether the biotinylated fibrinogenfrom irradiated tumors as compared to 0 of 106 wild-type and
colocalizes with the 2b chain of 2b3, LLC tumor sections were0 of 106 random sequence phage (p  0.001).
stained with Cy5-labled antibody for anti-2b antibody and Cy3-
labeled avidin. Figure 2F shows that fibrinogen (green) colocal-Radiation-induced accumulation of 2b3 integrin
izes (yellow) with 2b (red) within the tumor vascular lumen.within tumor blood vessels
The fibrinogen receptor, integrin 2b3, is therefore a candidateThe RGD sequence within the RGDGSSV peptide has the great-
est number of matches in Blast and Swisspro searches. Putative radiation-inducible receptor for site-specific drug delivery.
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Figure 1. Radiation-induced platelet aggregation in tumor microvasculature
GL261 murine gliomas were implanted into the hind limb of C57BL6 mice. Tumors were grown to a diameter of 10–12 mm over 8–10 days, followed by
irradiation. Six hours after irradiation, tumors were dissected and fixed. Shown is immunohistochemical staining for 3 chain (A and B); the 2b chain (C
and D) of integrin 2b3; and the av chain (E and F); and P-selectin (G and H). Shown are tumor sections obtained 6 hr after 0 Gy (upper panels), or 6 hr
after 6 Gy (lower panels). Arrows indicate area of positive staining.
I: Protein extracted from tumors shown in E and F was separated by SDS-PAGE. Shown is the autoradiograph from Western Immunoblot using antibody to
the 2b chain of integrin 2b3.
Drug delivery systems targeted During optimization studies, tumors were irradiated immedi-
ately before or immediately after tail vein injection. Both sched-to radiation-induced receptor
Drug delivery vehicles such as liposomes and nanoparticles can ules were effective in achieving 131I-fibrinogen-coated nanopar-
ticle binding. However, tumor irradiation after nanoparticlebe conjugated to fibrinogen to accomplish site-specific binding
to irradiated tumor blood vessels. Nanoparticles designed to administration achieved increased specificity of radiolabeled
protein binding as compared to tumors irradiated prior to admin-embolize tumor microvasculature include albumin within the
core, which can be radiolabeled with internal emitters for im- istration (Figure 3B). This finding could be explained by native
unlabeled fibrinogen in the circulation competing for activatedaging (Martodam et al., 1979; McGinity and O’Donnell, 1997;
Saltzman and Fung, 1997). To determine whether integrin 2b3 2b3 before the administration of Fbg-NP. Albumin nanopar-
ticles without fibrinogen conjugation were used as negative con-can serve as a target for imaging, fibrinogen-conjugated nano-
particles were radiolabeled. Nanoparticles consisting of an albu- trols. Control nanoparticles were radiolabeled with 131I and ad-
ministered by tail vein to mice bearing irradiated B16F0 tumors.min aggregate core, coated with fibrinogen (Fbg-NP), were ra-
diolabeled with 131I and administered by tail vein injection into Figure 3C shows that nanoparticles do not bind in irradiated
tumors unless they are coated with fibrinogen. To comparetumor bearing mice (Figure 3). GL261 glioma and B16F0 mela-
noma tumors were implanted into C57BL6 mice and irradiated tumor-specific binding of radiolabeled albumin nanoparticles to
that of radiolabeled Fbg-NP, we removed tumors and measuredwith 6 Gy. Specificity of Fbg-NP was determined by well counts
of tumor and other tissues. Figure 3 shows that 91% of counts tissue weight and well counts of tumor and whole body. The
ratio of (CPM tumor/weight tumor) to (CPM whole body/weightwere localized to tumors while 9% were diffusely distributed
throughout the entire animal model as compared to untreated whole body) showed 102-fold tumor specificity for Fbg-NP.
In comparison, radiolabeled albumin nanoparticles showed nocontrols, which showed 10% of counts in tumor (p  0.001).
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Figure 2. Peptide binding within intravital tumor
vascular window
LLC tumors were implanted into dorsal skin fold
windows of C57BL6 mice. Tumors were irradiated
and FITC-labeled peptide was administered.
Shown are fluorescent microscopic photographs
obtained at 6 hr after (A) irradiation and “scram-
bled” control peptide, (B) RGDGSSV peptide
and 0 Gy, (C) RGDGSSV peptide and 6 Gy.
Arrows indicate FITC-labeled peptide accumu-
lation within vasculature.
D and E: Biotinylated fibrinogen binding in irradi-
ated tumor blood vessels is shown. Tumors were
implanted into both hind limbs of mice. The right
tumor was irradiated and the left served as an
untreated internal negative control. Biotinylated
fibrinogen was administered by tail vein injection
immediately prior to tumor irradiation. Shown are
fluorescent microscopic photographs of (D) con-
trol and (E) irradiated tumors.
F: Colocalization of Fbg-NP with antibody to 2b.
Fbg-NP were biotinylated and injected by tail
vein into LLC tumor bearing mice. Tumors were
immediately irradiated using 6 Gy while shielding
the body of the mouse. Shown are microscopic
(100) photographs of tumor sections stained
with avidin and anti-2b antibody. Arrow indi-
cates nanoparticle and 2b co-staining.
increase in binding to irradiated tumor as compared to all other the administration of radiolabeled Fbg-NP. Figure 4 shows
normal tissues (Figure 3C). blood flow primarily in the periphery of all tumors and less flow
A potential limitation in the use of fibrinogen to target drug within the center of tumors. In comparison, the pattern of 
delivery is the risk of thromboembolic events in vital organs. To emission from 131I-labeld Fbg-NP is shown in the lower panels
determine whether fibrinogen-coated nanoparticles bind within of Figure 4. Gamma emission from tumor sections at 6 hr after
specific organs, we measured 131I in organs by use of well counts treatment shows that radiolabeled particles are distributed
and studied nanopartcle binding by microscopy. Figure 3D throughout the tumor sections, and are primarily localized to
shows 131I labeled nanoparticles quantified by well counts of the areas of higher blood flow. The distribution of  emission from
lungs, kidneys, livers, spleens, and hind limbs of each of the nanoparticles in tumor sections correlated well with the corre-
mice. The bar graph shows counts from each of these organs sponding patterns of blood flow imaged by Doppler.
comparing 131I -nanoparticle alone to 131I-Fbg-NP. Tumors trap Liposome conjugates are an alternative drug delivery vehicle
91% of Fbg-NP following irradiation, and the remaining 9% to nanoparticles. For example, antibody-liposome conjugates
binds primarily in the spleen (4.4%). The remaining 4.6% was have been used to target drug delivery to tumor blood vessels
distributed equally throughout the entire blood volume, with (Boerman et al., 2001; Sipkins et al., 2000). We conjugated
less than 1% in lung, liver, kidney, and hind limb, respectively. fibrinogen to long circulating liposomes. Liposomes were la-
There was no increase in Fbg-NP binding within the irradiated beled with the fluorescent marker DiI and administered by tail
hind limb as compared to untreated controls. Likewise, unirradi-
vein into mice bearing tumors on both hind limbs. The right
ated lungs, kidneys, and livers showed no increase in Fbg-
tumor was treated with radiation and the left tumor served asNP binding. Conversely, the spleen showed increased Fbg-NP
the untreated internal control. Untreated control tumors showedbinding as compared to uncoated nanoparticle controls (Figure
no fibrinogen-liposome conjugate binding (Figure 5A) whereas3D). Organs from mice shown in the bar graph were sectioned
tumors irradiated immediately before or immediately after tailand stained for biotinylated nanoparticles. Shown are represen-
vein injection showed fibrinogen-liposome in blood vessels (Fig-tative microscopic photographs of biotinylated Fbg-NP in lung
ure 5B). The fluorescent marker was found within the vascularand spleen. Fbg-NP were trapped within irradiated tumors and
lumen of tumor microvasculature. We studied the tumor-tar-little binding occurred within the spleens, and there was no
geting potential by radiolabeling the fibrinogen-liposome conju-increase in binding within blood vessels of other organs.
gates. Figure 5C shows that 89% of radiolabeled liposome con-Diminished binding in regions of low blood flow in tumors
jugates were localized to tumors treated with radiation afteris a second potential limitation of targeted drug delivery. To
administration of liposomes as compared to 9% in untreateddetermine the biodistribution of Fbg-NP within irradiated tu-
tumors (0 Gy) (p  0.001), while 75% of radiolabeled liposomemors, Fuji plate imaging of 131I-labeld Fbg-NP microdosimetry
conjugates were localized in tumors treated immediately afterwas performed. Blood flow in GL261, LLC, and B16F0 tumors
was imaged by Doppler blood flow (Geng et al., 2001) prior to injection.
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Figure 3. Fbg-NP were radioiodinated by use of
iodogen
A: B16F0 murine melanomas were implanted into
the hind limbs of C57BL6 mice. 131I-nanoparticles
were administered by tail vein injection and mice
were imaged by pinhole collimator on an Anger
 camera. Shown are images representative of
scans of mice following tumor irradiation with 0
Gy or 6 Gy after Fbg-NP administration. Arrows
show the location of tumor markers that were
imaged prior to 131I imaging.
B: Tumors were excised and well counts of tumor
and whole animal were measured. Shown are
the mean and SEM of well counts of whole body
(white bars) and tumor (black bars) from five
animals in each group.
C: Albumin nanoparticles serving as negative
controls were radiolabeled with 131I and adminis-
tered by tail vein to mice bearing irradiated tu-
mors. Shown are the mean and SEM of well
counts of whole body and tumor from mice in-
jected with Fbg-NP (diagonal stripes) or control
albumin nanoparticles (vertical stripes) in five an-
imals in each group.
D: 131I-labeled nanoparticles were quantified by
well counts of the lungs, kidneys, livers, spleens,
and hind limbs of each of the mice. The bar
graph shows percentage of total counts in each
organ from mice treated with Fbg-NP and radia-
tion (black bars), or control nanoparticles and
radiation (gray bars).
E: Organs from mice shown in Figure 3D were
sectioned and stained for biotinylated nanopar-
ticles. Shown are representative microscopic
photographs (100) of staining for nanoparticles
in lung and spleen. Yellow arrows indicate
stained Fbg-NP.
Tumor vascular response to
radiation-targeted nanoparticles
An advantage to targeting drug delivery to tumor vasculature
is that the blood vessels within neoplasms are effective thera-
peutic targets. To determine whether nanoparticles targeted to
radiation-inducible 2b3 can achieve tumor vascular obstruc-
tion, we studied blood flow in treated tumors. Amplitude modu-
lated three-dimensional Doppler sonography (Power Doppler)
quantifies tumor microvascular blood flow (Geng et al., 2001).
B16F0 hind limb tumors were irradiated and Fbg-NP were ad-
ministered by tail vein. Tumor blood flow was imaged by use
of Power Doppler prior to and 3 days after treatment (Figure 6).
Tumors were treated with 10 Gy, 10 Gy with uncoated nanopar-
ticles, 0 Gy, and 10 Gy with Fbg-NP. Sonographic measurement
of microscopic blood flow showed that radiation alone or nano-
particle controls achieved minimal change in tumor blood flow.
Tail vein administration of Fbg-NP immediately prior to irradia-Figure 4. Biodistribution of Fbg-NP within irradiated tumors
tion achieved tumor-specific reduction in tumor blood flow thatBlood flow in LLC, GL261, and B16F0 tumors was imaged by use of Doppler
sonography prior to the administration of radiolabeled Fbg-NP (upper pan- persisted at 72 hr after irradiation (Figure 6G). Quantification of
els). Tumors were sectioned 6 hr after the administration of Fbg-NP and blood flow showed an 85% reduction in tumors treated with
placed onto Fuji plates (lower panels). The distribution of Fbg-NP was com- Fbg-NP and radiation as compared to no change in tumors
pared to the pattern of blood flow in these same tumors. Shown are the
treated with 10 Gy or uncoated nanoparticles with 10 Gy (p patterns of  emission of tumor sections detected by Fuji imaging plates
and the corresponding patterns of blood flow imaged by Doppler. 0.023).
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Figure 5. Fibrinogen-liposome conjugates local-
ized to irradiated tumors
Thiolated fibrinogen was conjugated to malei-
mide containing liposome vesicles. Liposomes
were labeled with DiI fluorescent marker and ad-
ministered by tail vein to tumor bearing mice.
Tumors were treated with 4 Gy either prior to
administration or after administration of fibrino-
gen-liposome conjugates. Tumors were fixed
and sectioned at 24 hr following irradiation.
Shown are tumor sections of (A) sham irradiated,
(B) irradiation prior to fibrinogen-liposome ad-
ministration, and (C) irradiation after fibrinogen-
liposome administration. Fluorescence was im-
aged by UV microscopy (100).
D: Radiolabeled fibrinogen-conjugated lipo-
somes were administered to mice treated with 0
Gy, 6 Gy before injection, or 6 Gy after injection.
Shown are the percentages of well counts from
five tumors (black bars) and normal tissues (white
bars) after excision of tumors. * Irradiated tumors
show significantly increased 131I-Fibrinogen lipo-
some binding as compared to unirradiated tu-
mors (p  0.001).
Tumor vascular thrombosis could be activated by exoge- To validate the interaction between radiation and Fbg-NP,
the dorsal skin fold windows of LLC tumor blood vessels werenous fibrinogen or binding peptide alone. To determine whether
2b3 binding peptide or fibrinogen reduce tumor blood flow imaged by microscopy. Figure 7 shows representative micro-
scopic photographs of tumor vascular windows before (upperwhen combined with irradiation, these proteins were used as
panels) and after (lower panels) treatment with uncoated nano-controls. Tumors treated with fibrinogen and 10 Gy, or HHL
particles and radiation, Fbg-NP alone, or combined Fbg-NPGGAKQAGDV peptide and 10 Gy, showed no reduction in blood
and radiation. Tumor blood vessels treated with 3 Gy and Fbg-flow (Figure 6G). Fbg-NP are required to obstruct blood flow
NP were destroyed within 72 hr, whereas radiation and controlwithin tumors. The 2b-blocking antibody was used to deter-
nanoparticles or Fbg-NP alone produced minimal reduction inmine whether the biological effect required Fbg-NP binding to
tumor blood vessels (Figure 7). The bar graph shows the meana2bb3 receptor. Blocking antibody administered immediately
and SEM of five tumors in each of these treatment groups.prior to Fbg-NP and irradiation significantly attenuated the re-
Tumor blood vessels treated with 3 Gy and Fbg-NP had a meanduction in blood flow. Tumors treated with antibody showed
vascular linear density that was 5% that of the same tumorsblood flow that was 90% as compared to blood flow measured
prior to treatment (p  0.015). In comparison, radiation andprior to irradiation, while Fbg-NP and radiation reduced blood
control nanoparticles or Fbg-NP alone produced no significantflow to 15% as compared to blood flow at the 0 hr time point
reduction in tumor blood vessels to 91% and 83%, respectively.(p  0.048).
Disruption of blood flow by nanoparticles could be a nonspe-
cific effect of particle embolization within blood vessels. To Tumor regression and growth delay
Embolization or thrombosis of tumor vasculature can producedetermine the mechanism by which radiation and Fbg-NP dimin-
ish blood flow, tumor sections were stained for thrombus forma- tumor regression (Llovet et al., 2002; Hallahan et al., 1995a). To
determine whether radiation-induced activation of the fibrino-tion. Figures 6E and 6F show H&E staining of tumors irradiated
after tail vein injection of uncoated nanoparticles or Fbg-NP, gen receptor is a therapeutic target for vascular embolization,
we utilized fibrinogen-coated albumin nanoparticles. Fbg-NPrespectively. Arrows indicate thrombus formation within a
treated tumor blood vessel. In comparison, tumors treated with were administered immediately prior to irradiation of tumors.
Figure 8 shows fold increase in mean tumor volume as com-radiation and uncoated nanoparticles or treated with Fbg-NP
alone showed no thrombus formation (Figure 6E). pared to that measured on the day of treatment (Day 1). Fbg-
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Figure 6. Tumor blood flow analysis by use of ampulate modulated Doppler ultrasound
B16F0 hind limb tumors were imaged by Power Doppler sonography. Color area was recorded for the entire tumor. Shown are representative color
sonographic images of (A) 0 Gy, (B) 10 Gy alone, (C) 10 Gy and uncoated nanoparticles, or (D) 10 Gy and Fbg-NP. Increased signal intensity indicates
areas of high blood flow. Absence of signal indicates minimal blood flow.
E and F: Thrombus formation within tumors treated with Fbg-NP and radiation. Tumors shown in D were sectioned and stained with H&E. Shown are
microscopic photographs of tumors treated with 6 Gy and (E) uncoated nanoparticles, or (F) Fbg-NP. Arrow indicates thrombus formation within a treated
tumor blood vessel.
G: The bar graph shows the mean and SEM of power-weighted pixel density (PWPD) in ten mice entered into each treatment group. Signal intensity (color)
was quantified using HDI-lab software. Blood flow was measured in tumors at 0 hr and 72 hr after treatment with 0 Gy, 10 Gy alone, 10 Gy and uncoated
nanoparticles (NP), 10 Gy and Fbg-NP (Fbg-NP), fibrinogen and 10 Gy, HHLGGAKQAGDV peptide and 10 Gy, or 2b blocking antibody injected prior to
Fbg-NP and irradiation. The percent change in tumor blood flow is shown. Values for color area were averaged for each of the treated groups and are
compared to the same tumor prior to treatment by use of unpaired Student’s t test (**p  0.023; *p  0.048).
NP alone achieved no tumor regression and no significant Discussion
growth delay as compared to untreated control tumors. Radia-
tion alone achieved minimal growth delay as compared to un- Radiation-induced physiologic changes in tumor blood vessels
treated control tumors (p  0.11). Uncoated albumin nanopar- include conformational changes in pre-existing receptors or
ticles served as a negative control. When administered with transport of sequestered proteins (Hallahan et al., 1998). These
irradiation, albumin nanoparticles produced tumor growth rate
candidates for drug delivery cannot be detected by analysis ofthat was identical to that of tumors treated with radiation alone.
differential expression because protein and mRNA levels willFbg-NP administered with irradiation resulted in tumor regres-
not change. Therefore, we utilized phage displayed peptidesion and a significant growth delay as compared to tumors
libraries, which are useful discovery tools for the identificationtreated with uncoated albumin nanoparticles and irradiation (p
0.024). of tumor-specific receptors in animal models (Arap et al., 1998).
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Figure 7. Tumor vascular windows showing ab-
sence on hemoglobin within treated tumor
blood vessels
LLC tumors were implanted into the dorsal skin
fold window of C57BL6 mice. Shown are repre-
sentative microscopic photographs of tumor
vascular windows before (0 hr) and after (72 hr)
treatment with uncoated nanoparticles and ra-
diation alone, Fbg-NP alone, or combined Fbg-
NP and radiation. The bar graph shows the mean
and SEM of five tumors in each of these treat-
ment groups.
In the present study, the peptide library was injected into the
venous circulation and adhered to receptors in irradiated tumor
blood vessels. These phage peptides were then repeatedly re-
covered from irradiated tumors through several passages. Pep-
tides that bind nonspecifically to untreated blood vessels will
bind within other organs. The amino acid sequence RGDGSSV
was recovered from multiple tumor models and binds within
the tumor vascular lumen following irradiation. The 2b3 integ-
rin on platelets and the v3 integrin on endothelium play an
important role in angiogenesis (Reynolds et al., 2002; Trikha et
al., 2002; Silletti et al., 2001), and bind the RGD peptide se-
quence within tumor microvasculature (Hood et al., 2002; Mae-
shima et al., 2001). We studied selective ligands to v3 to
determine whether this is the binding site for the recovered
phage peptide RGDGSSV. There was no increase in the staining
for the v chain of integrin v3 in irradiated tumor vessels.
Moreover, we found no increased binding of v3 ligands to
tumor blood vessels following irradiation (D.H., unpublished
data). To determine the specificity of Fbg-NP binding, we utilized
2b- and v-blocking antibodies to compete for radiation-
induced ligand binding. This showed that the 2b antibody
prevented targeting of ligand, while the v-blocking antibody
Figure 8. Fold increase in mean tumor volume had no effect on ligand binding. Taken together with the findings
B16F0 tumors implanted into the hind limb of C57BL6 mice were treated that 2b3 accumulates in irradiated tumor blood vessels, the
with 10 Gy with or without the indicated nanoparticles. Tumor volumes were
fibrinogen receptor was selected for radiation-guided drug de-measured on the indicated days by use of calipers. Ten mice were entered
livery.into each of five groups (untreated control , radiation alone ð, Fbg-NP
alone O, Fbg-NP  radiation , and albumin nanoparticles  radiation 	). Fbg-NP and liposomes bind selectively within irradiated tu-
Uncoated albumin nanoparticles served as a negative control. Fbg-NP mor blood vessels. We found little to no binding in other organs.
administered with irradiation resulted in tumor regression and a significant
Platelets are activated during normal physiologic conditionsgrowth delay as compared to tumors treated with uncoated albumin nano-
particles and irradiation (p  0.024, Kruskal-Wallis). such as during wound repair. We have found that Fbg-NP bind
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to sites of mechanical injury (D.H., unpublished data). However, ligand binding within irradiated H460 human tumor xenografts
in nude mice, which showed site-specific drug delivery andthere were no thrombotic emboli to organs such as the brain,
lung, kidney, or liver. The spleen acts as a trap during the re- obliteration of tumor blood flow in a human xenograft.
The microvasculature is a therapeutic target in the treatmentmoval of activated platelets and Fbg-NP from the circulation.
Moreover, the mice do not develop tachypnea or hypomotility of cancer. One endothelial cell supplies nutrients to many tumor
cells. Tumor vasculature is therefore an effective therapeuticfollowing Fbg-NP injection and irradiation. Future phase I trials
could demonstrate the need to administer nanoparticle by an target in treatment of neoplasms (Folkman, 1995). Thrombotic
destruction of blood flow can achieve ischemia and subsequentintra-arterial approach; however, ongoing clinical trials have not
shown a risk of thrombotic events. A clinical trial designed to test tumor necrosis. Tumor vascular embolization is a strategy to
achieve obliteration of tumor blood flow. Platelet aggregationthe feasibility of targeting drug delivery to radiation-activated
integrins is underway. This clinical study utilizes the peptidomi- begins immediately after irradiation and accumulates over 6 hr,
when maximal platelet aggregation is achieved. In the presentmetic designed to evaluate deep venous thrombosis by binding
to activated 2b3 (Hallahan et al., 2001). Biapcitide (Acutect, study, Fbg-NP administered concurrently with irradiation re-
sulted in significant reduction in tumor blood flow and subse-Diatide/Berlex) is a structural analog of the RGD peptide. Biapci-
tide is labeled with 99Tc and administered to patients receiving quent tumor growth delay as compared to tumors treated with
uncoated albumin nanoparticles and irradiation. Fbg-NP canstereotactic radiosurgery or high dose rate brachytherapy. Our
preliminary data show that biapcitide binds to irradiated tumors accumulate by binding to the fibrinogen receptor on these acti-
vated platelets. The risk of thromboembolic events resultingand that 99Tc is selectively localized by use of irradiation.
Ionizing radiation induces the expression of antigens in the from fibrinogen-conjugated nanoparticles warrants further de-
velopment of targeted drug delivery to radiation-activatedvascular endothelium through posttranslational modification
and transcriptional induction of cell adhesion molecules and 2b3 integrin.
integrins (Hallahan et al., 1995b, 1996 1998; Hallahan and Viru-
Experimental proceduresdachalam, 1999). X-ray-induced activation of integrin 2b3 is
one potential radiation-inducible molecular target that can be
Recombinant T7 bacteriophage
exploited for drug delivery to tumor microvasculature. Radiation The T7 phage display system has the capacity to display peptides up to 15
is localized to the tumor through the use of conformal irradiation, amino acids in size at the high copy number (415 per phage). Unlike the
intensity-modulated radiotherapy, brachytherapy, and stereo- filamentous systems, peptides displayed on the surface of T7 are not capable
of secretion to the cell membrane as required for the filamentous phagetactic irradiation. The threshold dose for antigen induction can
assembly. T7 also replicates more rapidly and is extremely robust as com-be exceeded in the neoplasm, but avoided in the surrounding
pared to other phage. The stability allows for bio-panning selection proce-normal tissues. Ionizing radiation increases tumor vascular per-
dures, which require that phage remain infective. The T7 phage displaymeability (Yu et al., 2002). In the present study, uncoated nano-
system exploits the T7 capsid protein to display peptides on the surface of
particles and liposomes were used as controls to determine phage. The capsid gene 10 encodes a protein that is 348 amino acids in
whether tumor targeting was in part due to increased tumor length that can accommodate variation. The region of the capsid protein
vascular permeability. Uncoated control nanoparticles and lipo- unique to the 10B protein is on the surface of the phage and can be used
for phage display. Gene 10 encoding the capsid protein is cloned with asomes showed no increase in tumor localization following irradi-
series of multiple cloning sites at the C terminus of the 10B protein. Theation.
natural translational frameshift site within the capsid gene has been removedTumor-specific drug delivery has the potential to minimize
so that only a single form of the capsid protein is made. This results in atoxicity to normal tissues and improve bioavailability of cytotoxic
total of 415 recombinant peptides expressed on the surface of the phage.
agents to neoplasms (Arap et al., 1998; Kasahara et al., 1994). We utilized the recombinant bacteriophage library in T7 phage (Nova-
Existing site-specific drug delivery systems include adenovirus- gen). A population of DNA fragments encoding our recombinant peptide
targeted delivery to endothelial receptor v3 (Brooks et al., sequences was cloned into the T7 select vector, packaged into phage, and
amplified to prepare the library for bio-panning in the lab of E. Ruoslahti.1994; Wickham et al., 1995), and tumor-specific antigens (Ito
The ecoR1 estrogen enzyme site was selected to insert our random sequenceet al., 1991; Manome et al., 1994). Antibody conjugation to
of DNA segments. This allowed for directional cloning of prepared DNAcytotoxic agents has shown promise in achieving the goal of
inserts and expression in-frame with the 10B protein such that the recombi-
tumor-targeted cytotoxicity (Hellstrom et al., 1996; Pastan, nant fusion proteins were displayed. The resulting reading frame requires
1997). Liposome conjugation to proteins has also been used to the AAT (Asn) initial codon followed by a TCX (Ser) codon. Size-fractionated
deliver chemotherapy such as Doxorubicin to tumor-specific cDNA inserts were prepared by gel filtration on sepharose 4B and ranged
from 27 to 33 nucleotides. cDNAs were ligated by use of the DNA ligationantigens (Kirpotin, 1997). Each of these targeting approaches
kit (Novagen). The recombinant T7 DNA was then packaged in the packaginghas been limited by nonspecific binding to normal tissues or
extract provided by Novagen. The packaged recombinant phage displaylimited to very specific subsets of neoplasms, and by the small
library was then amplified prior to beginning the bio-panning in animal tumorsubsets of tumors that can be targeted by these antibodies,
models (Condron et al., 1991; Russel, 1991).
and by poor biodistribution of antibodies into solid tumors (Jain, Our goal was to discover peptides that bind within the vascular endothe-
1997). Alternative approaches to target all neoplasms exploit lium of all irradiated tumors. We therefore utilized two distinct tumor models
integrins and antigens on proliferating microvasculature (Burg including GL261 gliomas and B16F0 melanoma implanted into C57BL6 mice.
Tumors were implanted into the hind limb of mice. Tumors were then irradi-et al., 1999; Pasqualini and Ruoslahti, 1996). Radiation-inducible
ated with 3 Gy. The entire phage library was administered by intracardiacantigens include proteins in the microvasculature of irradiated
injection at 4 hr following irradiation. The mouse was then perfused withtumors, which are antigenic targets for site-specific drug deliv-
10 ml of PBS into the left ventricle that was recovered from the right atrium.ery to tumor blood vessels. The advantage in radiation targeting
Five minutes following irradiation, tumors were resected and phage were
of drug delivery is that the physiologic response of vasculature recovered from tumor homogenates. Tissue was disrupted by use of hand-
to radiation is similar among all tumors studied in this investiga- held homogenizer on ice. Recovered phage were then amplified 106-fold by
use of BL21 bacteria and subsequently administered to a second round oftion. In addition to GL261, B16F0, and LLC, we also studied
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irradiated tumors at 4 hr following treatment. Once again, tumors were 150
C overnight. Iodogen iodination solution was prepared by dissolving
resected and phage were recovered and amplified. This sequence was 1 mg iodogen in every 10 ml of chloroform. Ten milliliters of the prepared
repeated six times before sequencing of the capside DNA within the recov- iodogen iodination reagent solution was then added to each depyrogenized
ered phage. Following recovery from six sequential irradiated tumors, the 20 ml glass scintillation vial. The solvent was slowly evaporated off by gently
phage were plated in bacterial culture in auger. Lytic sites within the bacterial passing a stream of dry filtered nitrogen over it. When all the solvent had
culture were isolated and amplified. The DNA from 50 phage colonies was been evaporated, a fine white film of iodogen was evenly plated on the inner
sequenced. wall of the vessel. The vessels were sealed and placed in a desicator until
PCR was used to amplify the recombinant phage insert coding region use.
directly from the plaques. We sequenced 50 clones following six rounds of Each vial of peptides to be radioiodinated was stored at 0
C–4
C and
selection. We identified sequences that appear multiple times after six rounds was reconstituted immediately prior to radioiodination with 5 ml of sterile
of bio-panning. The PCR primer pair includes a T7 “up” primer, a 20-mer normal saline. The iodogen-plated reaction vessel was rinsed with a small
with the sequence AGC GGA CCA GAT TAT CGC TA (Novagen). The T7 amount of sterile saline to remove any loose microscopic flakes of the
“down” primer is a 20-mer with the sequence AACCCTCAAGACCCGTTTA. iodination reagent. The desired amount of carrier-free I-125 sodium iodide
The primer pair solution was prepared in 0.2 pmol/ul in water. The PCR were added to the reaction vessel, followed by the reconstituted peptides
beads were dissolved in 24 l of primer pair solution. The T7 plaque was suspension. We used a specific activity of 100 Ci/g protein. The reaction
suspended in 10 l of 1 tris-buffered saline. The PCR reaction mixture vessel was sealed off and the reaction was allowed to proceed for 20 min
was mixed with 1 l of phage suspension. The sequencing reaction was at room temperature with constant gentle agitation of the reaction vessel.
performed as described and separated by sequencing gel in an ABI 377 Radiolabeled protein was isolated by gel chromatography.
sequencer. GL261 murine gliomas and B16F0 murine melanomas were implanted
into the hind limb of C57BL6 mice. 131I-nanoparticles were administered by
Intravital tumor vascular window model tail vein injection and mice were imaged by pinhole collimator on an Anger
Gibco BRL penicillin-streptomycin solution (200 l) was injected into the
 camera.
hind limb of the mouse before the procedure. The dorsal skin fold window
is a 3 g plastic frame applied to the skin of the mouse and remains attached
Animal imaging and image analysis
for the duration of the study. The chamber was screwed together, while the
Tumor bearing mice were imaged at 1 hr and 24 hr time points post-adminis-
epidermis was incised and remained open with a plastic covering. During
tration of radiolabeled proteins. Planar pinhole  camera imaging was per-surgery, the area was kept moist by applying moist drops of phosphate-
formed on a single-head  camera (General Electric Helix) using a cone-buffered saline with 1% Penicillin/Streptomycin Solution. The bottom portion
shaped pinhole collimator with a 4 mm diameter Tungsten aperture. Pinholeof the chamber was put in place and the top was carefully positioned on
collimation offers the advantage of improved photon detection efficiencythe cut side so that the window and the circular incision were fitted. Antibiotic
(sensitivity) and spatial resolution when compared with conventional, parallelointment was applied at this time. Tumor blood vessels developed in the
multihole collimators. Pinhole planar imaging with a small source-aperturewindow within 1 week. Vascular windows were treated with 6 Gy using
separation can provide high-resolution images combined with large magni-superficial X-rays using 80kVp. FITC-labeled peptide (Genemed Synthesis,
fication. Each scan consisted of a 180 s acquisition (256  256 acquisitionInc., South San Francisco, California) was administered by tail vein immedi-
matrix) with a 10% energy window centered on 364keV. The source-apertureately prior to irradiation. Vascular windows were photographed using fluo-
separation was 6.0 cm. Prior to the animal studies, a uniform 131I disk sourcerescence microscopy and 4 objective to obtain a 40 total magnification.
was imaged in order to measure the angular dependence of the pinholeBinding of FITC-labeled peptide was photographed at 6 hr after irradiation.
collimator to gamma camera system detection efficiency with distance from
the center of the pinhole. Angular sensitivity, normalized to 1.0 at the centerImmunohistochemistry of tumor sections
of the pinhole, was then used to scale the mouse data in order to correctGL261 murine gliomas were implanted into the hind limb of C57BL6 mice.
image counts for this geometrical effect. A calibration source of known 131ITumors were grown to a diameter of 10–12 mm over 8–10 days. Tumors
activity was also scanned at a 6.0 cm source-aperture separation distancewere irradiated with 10 Gy and fixed 6 hr later. Immunohistochemical staining
in order to measure system sensitivity along the center of the pinhole.for P-selectin and integrin 2b3was performed for untreated control and
tumors 6 hr after irradiation. Sections were stained with rabbit anti-mouse
Fibrinogen conjugation to liposome2b or 3 antibodies (CD41/61; BD Sciences), and HRP-conjugated goat
anti-rabbit IgG (Vector Labs, Burlingame, California) as described (Hallahan The lipophilic SH reactive reagent with a long spacing arm was synthesized
and Virudachalam, 1999; Hallahan et al., 1998). from malimide-PGE 2000-NSH ester (Prochem), dioleoylphosphatidyletha-
nolanime (DOPE, Avanti Polar Lipids), and triethylamine in chloroform
Microsphere preparation (1:1:1.5). Resulting maleimide-PEG 2000-DOPE was purified by flash col-
Albumin nanoparticles (Martodam et al., 1979) were resuspended using 10 ml umn. Under stirring, 5 excess of freshly prepared Traut’s reagent in the
of sterile normal saline (0.9% NaCl). One half milliliter of the reconstituted same buffer was added to a solution of fibrinogen (2 mg/ml) in 0.01 M
microsphere was added to a 1.5 ml conical polypropylene tube previously HEPES 0.15 NaC1 buffer (pH 7.9), containing 10 mM EDTA and 0.08%
coated with Iodgen (Pierce, Rockford, Illinois). To this, 11.3 mCi (418 mega- NaN3. Reaction was performed for 30 min at 0
C. SH-fibrinogen was then
becquerel (MBq)) of 131I-Dupont (North Billerica, Massachusetts) NEZ-035H purified using a desalting PD-10 column. PGE 2000-PE, cholesterol, Dipalmi-
was added in approximately 11 l of saline and allowed to incubate at toyl phosphocholine (Avanti Polar Lips, AL), DiI (lipid fluorescent marker),
room temperature for 30 min. Following incubation, the nanoparticles were and maleimide-PEG-2000-DOPE were dissolved in chloroform and mixed
transferred to a 15 ml sterile centrifuge tube, diluted to 10 ml with normal at a molar ratio of 10:43:43:2:2 in a round bottom flask. The organic solvent
saline, and centrifuged at 1,500  “gravity” for 7 min. The supernatant was
was removed by evaporation followed by desiccation under vacuum for 2 hr.
removed and discarded. The nanoparticles were washed one additional
Liposomes were prepared by hydrating the dried lipid film in PBS at a lipidtime with 10 ml of normal saline and centrifuged. The nanoparticles were
concentration of 10 mM. The suspension was then sonicated 3  5 minsuspended in 2 ml of normal saline for injection. Final yield was 4.8 mCi
until clear, forming unilamellar liposomes of 100 nM in diameter. To conjugate(177.6 MBq) of radioiodinated nanoparticles in 2 ml saline. Radiochemical
thiolated fibrinogen to maleimide containing liposomes, prepared vesiclesyield was 42.4%. Nanoparticles were radiolabeled, and the radioiodination
and thiolated protein were mixed in 10 mm Hepes, 0.15M NaC1, and EDTAprocess was terminated by removing the reaction mixture from the reaction
(pH 6.5). The final concentrations for proteins and liposomes were 0.25 g/lvessel into a centrifugation tube. The reaction mixture was centrifuged at
and 2.5 mM, respectively. Mixture was incubated for 18 hr at RT and vesicles3000 rpm for 15 min. The supernatant were removed and the residue was
were separated from unconjugated protein by gel filtration (sepharose 4B-reconstituted in 5 ml sterile normal saline.
CL, Pharmacia).
Liposomes were fluorescently labeled with DiI fluorescent marker andPreparation and radioiodination of proteins
administered by tail vein to tumor bearing mice. Tumors were treated withTwenty milliliter glass scintillation vials were depyrogenized and sterilized
by rising them in deionized water followed by putting them into an oven at 4 Gy either prior to administration or after administration of fibrinogen-
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